NVCR News and Press, NovoCure Limited From 04/03/23

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the first quarter 2023 on Thursday, May 4, 2023, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss the company’s financial results for the three mo...

Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors. “We look forward to welcoming Ms. Stafford to our board of directors,” said William Doyle, Novocure’s Executive Chairman. “Her broad expertise in...

2023-03-27 05:22:43 ET Summary NovoCure has seen strong growth over the past decade but is unable to post profits with large sums invested into the pipeline. After softer sales momentum, pipeline conversion to other cancer types is necessary to drive appeal. Expectations have ...

2023-03-22 07:55:00 ET The use of bioelectronic devices for pain management is a growing industry expected to continue expanding in the coming years. Bioelectronic devices, also known as […] For further details see: Top Stocks in the Medical Device Boom (SWAV, EMED, NVCR, IRTC, M...

2023-03-20 15:02:25 ET Summary NovoCure focuses on promoting Optune and Optune Lua, FDA-approved devices utilizing Tumor Treating Fields (TTFields) technology to target and destroy cancer cells. The LUNAR study in non-small cell lung cancer (NSCLC) met its primary endpoint, showin...

Novocure (NASDAQ: NVCR) today announced the 5 th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program. The program represents a joint effort with the American Association for Cancer Research (AACR) to promote and support innovative research on Tumor Treating Fields (TTFields...

Novocure ( NASDAQ: NVCR ) said its device Optune will get reimbursement and was available with temozolomide (TMZ) in France to treat adult patients with newly diagnosed glioblastoma (GBM), a type of brain cancer. The company noted that the order registering Optune on th...

Optune is now available as a treatment for newly diagnosed glioblastoma patients in France Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in ...

Final data from the METIS study anticipated in 2024 Novocure (NASDAQ: NVCR) today announced that the final patient has enrolled in the pivotal METIS study evaluating the efficacy of Tumor Treating Fields (TTFields) therapy following stereotactic radiosurgery (SRS) for treatment of patie...

Shares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results release this morning. Specifically, the Tumor Treating Fields product (TTFields) pioneer's stock was down by a hefty 7.36% on heavy volume...